Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mary L Disis

Showing results (141-150 of 189) with videos related to

Pageof 19
Sort By:
Journal of Immunological Methods|December 13, 2005
Maximizing the retention of antigen specific lymphocyte function after cryopreservationMary L Disis, Corazon dela Rosa, Vivian Goodell, et al.
Gynecologic Oncology|January 17, 2017
Phase II trial of albumin-bound paclitaxel and granulocyte macrophage colony-stimulating factor as an immune modulator in recurrent platinum resistant ovarian cancerJohn B Liao, Ron E Swensen, Kelsie J Ovenell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2016
Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHNLaura Q M Chow, Chihiro Morishima, Keith D Eaton, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 18, 2016
Leveraging premalignant biology for immune-based cancer preventionAvrum Spira, Mary L Disis, John T Schiller, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 7, 2007
Functional T cell responses to tumor antigens in breast cancer patients have a distinct phenotype and cytokine signatureMargaret Inokuma, Corazon dela Rosa, Charles Schmitt, et al.
Evaluation & the Health Professions|September 26, 2013
Expanding assessments of translational research programs: supplementing metrics with value judgmentsCraig S Scott, Pamela R Nagasawa, Neil F Abernethy, et al.
BMC Immunology|March 28, 2008
Precision and linearity targets for validation of an IFNgamma ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptidesHolden T Maecker, Jeffrey Hassler, Janice K Payne, et al.
Gynecologic Oncology|October 3, 2024
Intraperitoneal immunotherapy with denileukin diftitox (ONTAK) in recurrent refractory ovarian cancerJohn B Liao, Nikita S Jejurikar, Katie M Hitchcock-Bernhardt, et al.
Cancer Research|June 19, 2008
An HLA-DR-degenerate epitope pool detects insulin-like growth factor binding protein 2-specific immunity in patients with cancerKimberly R Kalli, Christopher J Krco, Lynn C Hartmann, et al.
Cancer Research|March 17, 2006
10th Biennial Helene Harris Memorial Trust meetingFrances R Balkwill, Alan Ashworth, Robert C Bast, et al.
Pageof 19

Showing results (141-150 of 189) with videos related to

Sort By:
Pageof 19
Journal of Immunological Methods|December 13, 2005
Maximizing the retention of antigen specific lymphocyte function after cryopreservationMary L Disis, Corazon dela Rosa, Vivian Goodell, et al.
Gynecologic Oncology|January 17, 2017
Phase II trial of albumin-bound paclitaxel and granulocyte macrophage colony-stimulating factor as an immune modulator in recurrent platinum resistant ovarian cancerJohn B Liao, Ron E Swensen, Kelsie J Ovenell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2016
Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHNLaura Q M Chow, Chihiro Morishima, Keith D Eaton, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 18, 2016
Leveraging premalignant biology for immune-based cancer preventionAvrum Spira, Mary L Disis, John T Schiller, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 7, 2007
Functional T cell responses to tumor antigens in breast cancer patients have a distinct phenotype and cytokine signatureMargaret Inokuma, Corazon dela Rosa, Charles Schmitt, et al.
Evaluation & the Health Professions|September 26, 2013
Expanding assessments of translational research programs: supplementing metrics with value judgmentsCraig S Scott, Pamela R Nagasawa, Neil F Abernethy, et al.
BMC Immunology|March 28, 2008
Precision and linearity targets for validation of an IFNgamma ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptidesHolden T Maecker, Jeffrey Hassler, Janice K Payne, et al.
Gynecologic Oncology|October 3, 2024
Intraperitoneal immunotherapy with denileukin diftitox (ONTAK) in recurrent refractory ovarian cancerJohn B Liao, Nikita S Jejurikar, Katie M Hitchcock-Bernhardt, et al.
Cancer Research|June 19, 2008
An HLA-DR-degenerate epitope pool detects insulin-like growth factor binding protein 2-specific immunity in patients with cancerKimberly R Kalli, Christopher J Krco, Lynn C Hartmann, et al.
Cancer Research|March 17, 2006
10th Biennial Helene Harris Memorial Trust meetingFrances R Balkwill, Alan Ashworth, Robert C Bast, et al.
Pageof 19